Looking to know more about the role of the right ventricle in the pathophysiology of tricuspid regurgitation? Don’t miss this video!

You’ll learn how to assess RV function and morphology with advanced imaging, uncover key parameters that predict outcomes, understand how RV remodeling impacts procedural success, and...

Curious about managing multivalve disease in the absence of robust clinical evidence? This video is a must-watch!

You'll explore the latest strategies for assessing and treating this condition (including advanced multimodality investigations like echocardiography, magnetic resonance and cardiac catheterisation), and learn how to evaluate cardiopulmonary interactions and...

Explore the latest advancements in aortic valve research during this featured session, showcasing selected abstracts from the upcoming PCR London Valves 2024 conference. Delve into topics ranging from the long-term outcomes of bailout valve-in-valve TAVI, the performance of the Navitor THV in bicuspid aortic valves, novel...

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Ali Nazmi Calik provides a summary and key take-aways and infographics of 9 major trials of interest to interventional cardiologists presented at ACC.21

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.